• > 90% diagnostic accuracy

  • ~ 70% reduction in indeterminate diagnoses

  • > 80% reduction of overtreatment in myPath Benign cases


Fact Sheets and Product Info:

Photo of man working on roof

Executive Summary

 Download PDF

Closeup photo of scientific graph

Tech Specifications

 View Info


About Melanoma:

Melanoma is an aggressive cancer with an estimated 96,480 cases and 7,320 deaths in 2019. The lifetime risk of developing melanoma in the United States is 1 in 34 for men and 1 in 54 for women.

However, many melanomas are curable if they are detected early and diagnosed accurately. The 10-year survival rate for patients with stage I melanomas is 86-95%, compared with only 10-15% among patients with stage IV melanomas.


About myPath Melanoma:

myPath Melanoma may be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. Reasons that definitive diagnosis may not be achievable by histopathology include indeterminate/ambiguous histopathologic features, diagnostic disagreement among physicians, or indications that additional workup or consultation are necessary.